Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial

This phase I/II trial examined safety and efficacy of the toll-like receptor 2/6 agonist MALP-2 in combination with gemcitabine in patients with incompletely resectable pancreas carcinomas. MALP-2 is a toll-like receptor 2/6 agonist, acts as an immunological adjuvant, and has been described recently...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, J, Welsch, T, Jäger, D, Mühlradt, P F, Büchler, M W, Märten, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360370/
https://www.ncbi.nlm.nih.gov/pubmed/17667928
http://dx.doi.org/10.1038/sj.bjc.6603903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360370/
https://www.ncbi.nlm.nih.gov/pubmed/17667928
http://dx.doi.org/10.1038/sj.bjc.6603903

Ejemplares similares